SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Yescarta

GILD·GILEAD SCIENCES, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available since October 2017.
Actionable Insight NEUTRAL

Yescarta has no scheduled PDUFA date or pivotal readout in the next 12 months. The next catalyst to watch is the Q4 2026 earnings release (late January/early February 2027) for the sales trajectory and any commentary on competitive dynamics versus Breyanzi and Carvykti. Longer term, watch for any data from Kite's next-generation CAR-T programs or label expansion studies that could reverse the sales decline.

Price Chart

Loading chart...

Executive Summary

Yescarta (axicabtagene ciloleucel) is a CD19-directed CAR-T cell therapy developed by Kite Pharma, a subsidiary of Gilead Sciences (GILD). First approved by the FDA in October 2017 for relapsed/refractory large B-cell lymphoma, it now carries multiple approved indications including second-line LBCL (ZUMA-7, 2022), follicular lymphoma (ZUMA-5, 2021), and a February 2026 label update removing limitations of use for primary CNS lymphoma. Yescarta is a mature, marketed product facing intensifying competition from Bristol Myers Squibb's Breyanzi, Novartis' Kymriah, Johnson & Johnson's Carvykti, and others. Sales are in decline: Q3 2026 revenue was $294 million, down 16% year-over-year, and full-year 2025 sales were approximately $1.5 billion. For Gilead, a $165 billion diversified biopharma, Yescarta is a meaningful but not dominant revenue contributor, with no upcoming binary regulatory catalyst on the horizon.

How It Works

Yescarta is a personalized cancer immunotherapy. A patient's own immune cells (T cells) are collected, genetically modified in a lab to recognize and attack cancer cells that carry a protein called CD19, and then infused back into the patient. This is known as CAR-T cell therapy. It is a one-time treatment designed to train the immune system to fight certain types of blood cancers (lymphomas).

Trial Status

Yescarta is FDA-approved across multiple indications based on the ZUMA-1 (third-line LBCL, 2017), ZUMA-5 (follicular lymphoma, 2021), and ZUMA-7 (second-line LBCL, 2022) trials. The ZUMA-7 study demonstrated a statistically significant overall survival benefit versus standard of care, with 5-year follow-up data published in the New England Journal of Medicine. A February 2026 label update removed previous limitations of use for relapsed/refractory primary CNS lymphoma based on safety data. Ongoing analyses include real-world evidence and combination studies.

The Two-Sided Case

▲ Bull Case4
Yescarta is a first-in-class, first-to-market CAR-T therapy for LBCL with a well-established safety and efficacy profile across multiple indications.
The ZUMA-7 trial showed a statistically significant overall survival benefit versus standard of care, strengthening the drug's clinical positioning as second-line therapy.
The February 2026 FDA label update removing PCNSL limitations of use opens access to a new patient population with a rare and aggressive lymphoma.
Gilead's Kite subsidiary continues to invest in real-world evidence and manufacturing improvements that could support outpatient administration and broader access.
▼ Bear Case4
Yescarta sales are declining: Q3 2026 revenue fell 16% year-over-year to $294 million, with Q2 2026 down 12% and Q1 2026 down 14%, driven by in- and out-of-class competition.
The CAR-T competitive landscape is increasingly crowded with at least five approved CD19-directed products in the US/EU (Breyanzi, Kymriah, Tecartus, Aucatzyl) plus emerging Chinese competitors.
Bristol Myers Squibb's Breyanzi has been expanding into earlier lines of therapy, directly competing with Yescarta's second-line LBCL indication.
Gilead's cell therapy franchise (Yescarta + Tecartus) is a small and shrinking portion of total revenue, limiting the stock-level impact of any positive developments for Yescarta alone.

Upcoming Catalysts

  • No upcoming PDUFA dates or pivotal readouts identified for Yescarta in the next 12 months.
  • Q4 2026 / full-year 2026 earnings release (late January/early February 2027) will provide updated sales trajectory and competitive commentary.
  • ASH or other medical conference data presentations on real-world evidence or long-term follow-up from ZUMA-7.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GILEAD SCIENCES, INC. 8-K GILD ·Originating report

Sources · 15

Hover a chip for the title
1 gilead.com2 gilead.com3 fda.gov4 drugs.com5 gilead.com6 pdufa.bio7 investors.com8 fiercepharma.com9 gilead.com10 nejm.org11 en.wikipedia.org12 eureka.patsnap.com13 s29.q4cdn.com14 investors.gilead.com15 gilead.com